olaratumab   Click here for help

GtoPdb Ligand ID: 9172

Synonyms: IMC-3G3 | Lartruvo® | LY3012207
Approved drug
olaratumab is an approved drug (EMA & FDA (2016))
Compound class: Antibody
Comment: Olaratumab is a fully human anti-platelet-derived growth factor receptor α (PDGFRα) monoclonal antibody, developed by Eli Lilly (link to Lilly's olaratumab webpage here), originally developed by ImClone Systems, Inc. [2].
Peptide sequences and structural information for this antibody are available from its IMGT/mAb-DB record. BLAST peptide sequence analysis reveals identical matches with sequences 8 and 16 from patent US8128929, and directly to clone IMC-3G3 [1]. From patent US8128929 it appears that the epitope recognised by olaratumab overlaps the PDGFRα binding sites for PDGF-AA and PDGF-BB.
Click here for help
1. Loizos N, Huber J. (2012)
Antibodies against PDGFRa.
Patent number: US8128929. Assignee: Imclone Llc. Priority date: 17/06/2006. Publication date: 06/04/2012.
2. Loizos N, Xu Y, Huber J, Liu M, Lu D, Finnerty B, Rolser R, Malikzay A, Persaud A, Corcoran E et al.. (2005)
Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target.
Mol Cancer Ther, 4 (3): 369-79. [PMID:15767546]